Abstract
Background Guillain-Barre syndrome (GBS) is an acute, paralyzing, inflammatory peripheral nerve disease. For treatments of the Guillain-Barre Syndrome, there are many kinds of therapies for this diseases. For comparing all of the therapies, such as immunoglobulin, plasma exchanging, etc. in the treatment of Guillain-Barre Syndrome(GBS) to better inform clinical practice, we used Network meta analysis to get the outcome of the Guillain-Barre Syndrome. The protocol had been submitted to PROSPERO:CRD: 42019119178.
Methods Web of Science, PubMed, Embase, and the Cochrane library were searched for related articles. We identified citations and of these included 28 trials comprising 2474 patients and control group human beings. Network meta-analysis (NMA) was performed with two kinds of outcomes. We carried on R software with gemtc package and JAGS software to calculate results for different therapies. The consistency of direct and indirect evidence was also assessed by R software.
Results Concerning for two outcomes, there were no improvement observed in methylprednisolone and prednisolone compared with placebo. PE and IVIg were illustrated to be effective over Placebo. There was no significant difference between different doses and times of PE and IVIg. On consistency examination between direct and indirect evidences, there were no obvious heterogeneity between all of therapies. Funnel plots indicates the possibility of publication bias in this study is small.
Conclusion PE or IVIg have a significant efficiency for GBS patients. The effect of some combination treatments should be further explored. Corticosteroids have no significant effects on GBS.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
PROSPERO:CRD: 42019119178
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=119178
Funding Statement
This work was funded by National Natural Science Foundation of China(No.81673910). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All codes and data are available. The data URLs will be open after accepted.
Abbreviations
- NMA
- network meta analysis
- GBS
- Guillain-Barre Syndrome
- MTP
- Methylprednisolone
- PbO
- Placebo
- Pred
- Prednisolone
- BDNF
- Brain-derived neurotrophic factor
- CSF filter
- Cerebrospinal fluid filtration
- PE
- Plasma exchange
- IVIg
- Intravenous immunogloblin 0.4–0.5 g/kg daily for 4–6 days
- PE+IVIg
- PE followed by IVIg
- IAPP+IVIg
- Immunoabsorption followed by IVIg
- IAPP
- Immunoabsorption plasmapheresis
- Twice IVIg
- 1 g/kg for 2 days
- Half IVIg
- 0.4 g/kg for 3 days
- Half PE
- Half course of PE
- TWP
- Tripterygium Wilfordii Polyglycoside
